Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies
Status:
Completed
Trial end date:
2012-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety and tolerability of CA-18C3 in subjects
with hematologic malignancies, as well as look at the preliminary efficacy of IL-1alpha
blockade.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC XBiotech, Inc.